Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients.

Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients. Abstract Text:

Hepcidin has recently been recognized as a hormone essential to the negative regulation of iron. Synthesis of hepcidin is increased by iron overload or inflammation, and decreased by iron deficiency, anemia and erythropoietin. Dialysis patients frequently suffer the effects of both hepcidin increasing and decreasing factors. In this study, we investigated, for the first time, pro-hepcidin in dialysis patients while minimizing or manipulating these factors. We measured the serum pro-hepcidin in 23 hemodialysis patients without inflammation (the HD group) and 10 age-matched healthy volunteers. Those patients in the HD group were assigned to an iron-deficiency group (the ID group) or a non-iron deficiency subgroup (non-ID group). The HD group was followed up for two months. Iron therapy was performed in the ID group during the follow-up period. At the end of this time we evaluated the influence of iron therapy. Pro-hepcidin was similar in the HD groups and the healthy controls (295.1 [241.9, 413.7] vs. 301.7 [280.5, 383.5] ng/mL; not significant) despite the presence of hepcidin-decreasing factors. Pro-hepcidin in the ID group was significantly lower than in the non-ID group (262.6 [233.1, 295.1] vs. 359.2 [282.3, 446.5] ng/mL; P < 0.05). In patients newly acquiring ID during follow-up without iron supplementation, pro-hepcidin fell significantly (from 444.7 [389.4, 470.1] to 299.8 [233.4, 330.4] ng/mL; P < 0.05). Pro-hepcidin also showed an increase after ID was treated with iron administration (from 246.9 [205.5, 329.1] to 344.6 [290.1, 377.9] ng/mL; not significant). Pro-hepcidin could serve as a marker for functional iron deficiency and disordered iron utilization in HD. Underlying mechanisms and improvements in measurement techniques will require additional investigation.

Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Therapeutic apheresis and dialysis : official peer

VOLUME: 12

Page Numbers: 226-31

Journal Abbreviation:

ISSN: 1744-9987

DAY: 27

MONTH: Jun

YEAR: 2008

Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101181252

Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients.

AFFILIATION: Division of Nephrology and Dialysis Center, Kobe University School of Medicine, Kobe, Japan.

Country: Australia

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Ther Apher Dial

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients Related Publications

• A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy.
• Age-related differences in insulin-like growth factor-1 receptor signaling regulates Akt/FOXO3a and ERK/Fos pathways in vascular smooth muscle cells.
• Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment.
• Bone formation in spontaneously diabetic Torii-newly established model of non-obese type 2 diabetes rats.
• CENP-O Class Proteins Form a Stable Complex and Are Required for Proper Kinetochore Function.
• Down-regulation of manganese-superoxide dismutase through phosphorylation of FOXO3a by Akt in explanted vascular smooth muscle cells from old rats.
• Dynamic behavior of Nuf2-Hec1 complex that localizes to the centrosome and centromere and is essential for mitotic progression in vertebrate cells.
• Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress.
• Protein and energy interactions throughout life. Metabolic basis and nutritional implications.
• Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients.
• Putative role of endothelial lipase in dialysis patients with hypoalbuminemia and inflammation.
• Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients.
• Spontaneous remission of severe hyperparathyroidism with normalization of the reversed whole PTH/intact PTH ratio in a haemodialysis patient.
• The kinetochore and spindle checkpoint in vertebrate cells.
• Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
• Whole or fragmentary information on parathyroid hormone?
• [Basic and Clinical Aspects of Calcimimetics. Calcimimetics : a promising treatment for persistent hypercalcemia after kidney transplantation.]
• [Basic and Clinical Aspects of Calcimimetics. Cinacalcet, effect and mechanisms of action.]
• [Basic and Clinical Aspects of Calcimimetics. Treatment of secondary hyperparathyroidism in dialysis patients with calcimimetics.]
• [The metabolic syndrome and bone health. The Relationship Between Lipid and Glucose Metabolism and Bone Mineral Metabolism : Pleiotropic effects of therapeutic agents for diabetes and hyperlipidemia.]